Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, Mori M, Mauro MJ, Deininger MW, Druker BJ. Press RD, et al. Among authors: deininger mw. Blood. 2006 Jun 1;107(11):4250-6. doi: 10.1182/blood-2005-11-4406. Epub 2006 Feb 7. Blood. 2006. PMID: 16467199 Free PMC article. Clinical Trial.
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW. Griswold IJ, et al. Among authors: deininger mw. Mol Cell Biol. 2006 Aug;26(16):6082-93. doi: 10.1128/MCB.02202-05. Mol Cell Biol. 2006. PMID: 16880519 Free PMC article.
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Agarwal A, Bumm TG, Corbin AS, O'Hare T, Loriaux M, VanDyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, Deininger MW. Agarwal A, et al. Among authors: deininger j, deininger mw. Blood. 2008 Sep 1;112(5):1960-70. doi: 10.1182/blood-2007-09-113860. Epub 2008 Jun 17. Blood. 2008. PMID: 18559973 Free PMC article.
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. Sherbenou DW, et al. Among authors: deininger mw. Blood. 2010 Oct 28;116(17):3278-85. doi: 10.1182/blood-2008-10-183665. Epub 2010 Jun 2. Blood. 2010. PMID: 20519627 Free PMC article.
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ. O'Hare T, et al. Among authors: deininger mw. Blood. 2011 Nov 10;118(19):5250-4. doi: 10.1182/blood-2011-05-349191. Epub 2011 Sep 8. Blood. 2011. PMID: 21908430 Free PMC article.
265 results